Lercanidipine

Lercanidipine, the active ingredient in Lercanidipine, is a dihydropyridine calcium channel blocker presented as a tablet for oral use. It lowers elevated blood pressure in adult patients diagnosed with hypertension.\n\nGNH India supplies Lercanidipine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is used to manage high blood pressure by relaxing vascular smooth muscle.\n\nHypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.\n\nCommon Side Effects:\n- Headache: mild to moderate intensity.\n- Flushing: transient warmth and redness of the skin.\n- Peripheral edema: swelling of ankles or lower legs.\n- Dizziness or light‑headedness, especially after standing.\n- Tachycardia: increased heart rate.\n- Nausea: occasional stomach upset.\n\nSerious or Rare Side Effects:\n- Severe hypotension: marked drop in blood pressure requiring medical attention.\n- Myocardial infarction: rare but possible in susceptible patients.\n- Hepatic dysfunction: elevated liver enzymes or hepatitis.\n- Allergic reactions: rash, pruritus, or anaphylaxis.\n- Angio‑edema: swelling of face, lips, or throat.\n- Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.\n\nMonitor blood pressure regularly: ensure therapeutic response and avoid excessive lowering.\nAssess hepatic function: dose adjustment may be needed in moderate to severe liver impairment.\nUse caution in the elderly: increased sensitivity to hypotensive effects.\nAvoid abrupt discontinuation: taper dose to prevent rebound hypertension.\nReview concomitant medications: especially other antihypertensives or CYP3A4 inhibitors.\nStore at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, altering its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension.\n- Simultaneous use with other potent vasodilators (e.g., nitroglycerin): can cause severe blood pressure drops.\n- Grapefruit juice: enhances drug exposure leading to adverse effects.\n\nModerate Interactions (Monitor Closely):\n- Other antihypertensives (e.g., ACE inhibitors, beta‑blockers): may require dose adjustments.\n- Diuretics: can amplify orthostatic hypotension.\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.